Oncostatin M/OSM Antibody [Unconjugated]

CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." > CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." title="Oncostatin M/OSM was detected in immersion fixed frozen sections of mouse embryo (15 d.p.c, section through spinal cord) using Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." />

Oncostatin M/OSM was detected in immersion fixed frozen sections of mouse embryo (15 d.p.c, section through spinal cord) using Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # <a class=

CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." > CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." title="Oncostatin M/OSM was detected in immersion fixed frozen sections of mouse embryo using Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections." />

Oncostatin M/OSM was detected in immersion fixed frozen sections of mouse embryo using Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # <a class=

495-MO) stimulates proliferation in the NIH‑3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse Oncostatin M/OSM (15 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA). The ND₅₀ is typically 0.6-3.0 µg/mL." > 495-MO) stimulates proliferation in the NIH‑3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse Oncostatin M/OSM (15 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA). The ND₅₀ is typically 0.6-3.0 µg/mL." title="Recombinant Mouse Oncostatin M/OSM (Catalog # 495-MO) stimulates proliferation in the NIH‑3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse Oncostatin M/OSM (15 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Oncostatin M/OSM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-495-NA). The ND₅₀ is typically 0.6-3.0 µg/mL." />

Recombinant Mouse Oncostatin M/OSM (Catalog # <a class=

OSM suppresses SMAD signaling. a After pretreatment with the OSM (10 ng per ml) or IL6 (20 ng per ml), C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression level of alpha SMA mRNA was calculated. The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (2, 6) = 97.35). b Immunoblot analysis of phospho-ERK1/2, total ERK1/2, phospho-SMAD2 linker (Ser245/250/255) and total SMAD2 protein. Thirty minutes after U0126 (20 nM) pretreatment, C3H/10T1/2 cells were stimulated with OSM (10 ng per ml) or IL6 (20 ng per ml) for 30 min. and collected for the analysis. U0126: a selective MEK1/2 inhibitor. c Immunoblot analysis of phospho-SMAD2 C-terminal (Ser465/467) and Lamin A/C. Thirty minutes after OSM (10 ng per ml) pretreatment, C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and collected at indicated time points. d After pretreatment with U0126 (20 μM, 60 min) and OSM (10 ng per ml, 30 min), C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression level of alpha SMA mRNA was calculated. Two-tailed t-test with Welch’s correction was used for the statistical analysis (t = 3.212, df = 3.172). Data show the mean and the standard deviation (error bar) of technical triplicates from a representative experiment (a, d). *p < 0.05. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31249305), licensed under a CC-BY license. Not internally tested by R&D Systems.

Oncostatin M from hypoxic MΦ inhibits fibroblast activation. a Supernatants were collected from thioglycollate-elicited peritoneal macrophages (TEPMs) under normoxic or hypoxic condition. After pretreatment with the supernatants, C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated (right). The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (2, 6) = 6.019). b We performed transcriptome analysis in isolated primary TEPMs from hematopoietic/endothelial-specific HIF-1 alpha conditional knockout mice (HIF-1 alpha flox/flox; Tie2-cre+/− mice; HIF-1 alpha KO) or cre negative littermate control. Flow chart shows the strategy to identify hypoxia-inducible secretory factors (left). Table illustrates the identified 11 hypoxia-inducible secretory factors (right). c The effect of each hypoxic inducible secretory factor in fibroblasts activation was examined (20 ng per ml for CTGF, CXCL2, CXCL3, LIF and 10 ng per ml for OSM). Thirty minutes after pretreatment with hypoxia-inducible secretory factors, C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated. The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (5, 12) = 68.07). d The effect of oncostatin M (OSM) (10 ng per ml) in primary cardiac fibroblasts activation was examined. Thirty minutes after pretreatment with OSM (10 ng per ml, 12 h), C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated. Two-tailed t-test with Welch’s correction was used for the statistical analysis (t = 10.89, df = 2.208). Data show the mean and the standard deviation (error bar) of technical triplicates from a representative experiment. e Immunohistological staining were performed using cardiac tissues from TAC operated mice (day 3). OSM (left), CD11b (right). Scale bar

Oncostatin M from hypoxic MΦ inhibits fibroblast activation. a Supernatants were collected from thioglycollate-elicited peritoneal macrophages (TEPMs) under normoxic or hypoxic condition. After pretreatment with the supernatants, C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated (right). The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (2, 6) = 6.019). b We performed transcriptome analysis in isolated primary TEPMs from hematopoietic/endothelial-specific HIF-1 alpha conditional knockout mice (HIF-1 alpha flox/flox; Tie2-cre+/− mice; HIF-1 alpha KO) or cre negative littermate control. Flow chart shows the strategy to identify hypoxia-inducible secretory factors (left). Table illustrates the identified 11 hypoxia-inducible secretory factors (right). c The effect of each hypoxic inducible secretory factor in fibroblasts activation was examined (20 ng per ml for CTGF, CXCL2, CXCL3, LIF and 10 ng per ml for OSM). Thirty minutes after pretreatment with hypoxia-inducible secretory factors, C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated. The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (5, 12) = 68.07). d The effect of oncostatin M (OSM) (10 ng per ml) in primary cardiac fibroblasts activation was examined. Thirty minutes after pretreatment with OSM (10 ng per ml, 12 h), C3H/10T1/2 cells were stimulated with TGF-beta 1 (2.5 ng per ml, 12 h) and the relative expression of alpha SMA mRNA was calculated. Two-tailed t-test with Welch’s correction was used for the statistical analysis (t = 10.89, df = 2.208). Data show the mean and the standard deviation (error bar) of technical triplicates from a representative experiment. e Immunohistological staining were performed using cardiac tissues from TAC operated mice (day 3). OSM (left), CD11b (right). Scale bar

UMAP visualization of skin scRNAseq analysis. (A) UMAPs of scRNAseq from skin punches of FT+/− and WT neonates treated with Alt or Alt/PNE with cluster-specific cell type annotation. (B) UMAP projection of skin cells expressing Osm (green), Areg (blue), and Il33 (red) above the threshold expression value (Seurat log Normalized) >1.5. Annotated cell type designation to numbered clusters in (A) is listed as follows; Dendritic, dendritic cells; Endo, endothelial cells; Fib, fibroblasts; ILC, innate lymphoid cells; KC, keratinocytes; Mac, macrophages; PMN, neutrophils; SM, smooth muscle cells; Stem, stem cells. (C) Cell clusters with abundant gene expression of Osm, Areg, and Il33. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35387035), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Oncostatin M/OSM Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse OSM
  Ala24-Arg206
  Accession # P53347
• Specificity: Detects mouse OSM in direct ELISAs and Western blots. In direct ELISAs, less than 2% cross-reactivity with recombinant human OSM is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: OSM
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.6-3.0 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Oncostatin M/OSM Antibody [Unconjugated]

• MGC20461
• oncostatin M
• oncostatin-M
• OSM

Background

Oncostatin M (OSM) is a member of a cytokine subfamily that includes IL-6, IL-11, LIF, CNTF, and cardiotrophin-1. These cytokines have overlapping biological functions and shared receptor components. Mouse OSM was cloned and identified as an immediate early gene induced in various myeloid and lymphoid cell lines by a subset of cytokines including IL-2, IL-3, GM-CSF, and EPO. The mouse OSM cDNA encodes a 263 amino acid residue precursor protein that shows 48% identity with human OSM. Similar to human OSM, the C-terminal region of mouse OSM contains a highly charged region. Deletion of this C-terminal region appears to be essential for the formation of biologically active mOSM.

The biological activity of human OSM has been shown to be mediated either by the LIF/OSM receptor complex composed of gp130 and LIF R alpha or by a human OSM specific receptor composed of gp130 and OSM R alpha . It remains to be determined if the biological activities of mouse OSM can also be mediated by both receptor complexes in mouse cells.

1. Yoshimura, A. et al. (1996) The EMBO Journal 15:1055.
2. Ray, P. et al. (1996) Endocrinology 137:1151.
3. Rose, T.M. and A.G. Bruce (1994) in Guidebook to Cytokines and Their Receptors, N.A. Nicola, editor, Oxford University Press, New York, p. 127.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Oncostatin M/OSM Antibody (AF-495-NA)(19)

Publications using AF-495-NA

• Yaghi, OK;Hanna, BS;Langston, PK;Michelson, DA;Jayewickreme, T;Marin-Rodero, M;Benoist, C;Mathis, D; A discrete 'early-responder' stromal-cell subtype orchestrates immunocyte recruitment to injured tissue Nature immunology 2023-11-06 [PMID: 37932455] (Neutralization, Mouse)
• Wang, Z;Yan, B;Tang, M;Jin, D;Lai, P; Tuberous sclerosis complex 1 targeted depletion in macrophages promotes osteogenesis by modulating secretion of Oncostatin M in the inflammatory stage of bone healing International immunopharmacology 2023-09-07 [PMID: 37688912] (Western Blot, IHC, Mouse)
• Haensel, D;Daniel, B;Gaddam, S;Pan, C;Fabo, T;Bjelajac, J;Jussila, AR;Gonzalez, F;Li, NY;Chen, Y;Hou, J;Patel, T;Aasi, S;Satpathy, AT;Oro, AE; Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche Nature communications 2023-05-10 [PMID: 37164949] (In vivo assay, Mouse)
• Y Song, J Yang, T Li, X Sun, R Lin, Y He, K Sun, J Han, G Yang, X Li, B Liu, D Yang, G Dang, X Ma, X Du, B Zhang, Y Hu, W Kong, X Wang, H Zhang, Q Xu, J Feng CD34+ cell-derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis Science Advances, 2023-04-12;9(15):eadd2632. 2023-04-12 [PMID: 37043578] (Flow Cytometry, Neutralizing, Mouse)
• T Komori, Y Morikawa Essential roles of the cytokine oncostatin M in crosstalk between muscle fibers and immune cells in skeletal muscle after aerobic exercise The Journal of Biological Chemistry, 2022-11-09;0(0):102686. 2022-11-09 [PMID: 36370846] (IHC, Western Blot, Mouse)
• Lauren M. Buelow, Akihiko Hoji, Kiet Tat, Lindsay M. Schroeder-Carter, Daniela J. Carroll, Joan M. Cook-Mills Mechanisms for Alternaria alternata Function in the Skin During Induction of Peanut Allergy in Neonatal Mice With Skin Barrier Mutations Frontiers in Allergy 2021-09-06 [PMID: 35387035] (In vivo assay, Mouse)
• Lauren M. Buelow, Akihiko Hoji, Kiet Tat, Lindsay M. Schroeder-Carter, Daniela J. Carroll, Joan M. Cook-Mills Mechanisms for Alternaria alternata Function in the Skin During Induction of Peanut Allergy in Neonatal Mice With Skin Barrier Mutations Frontiers in Allergy 9/6/2021 [PMID: 35387035]
• H Lörchner, JM Adrian-Seg, C Waechter, R Wagner, ME Góes, N Brachmann, K Sreenivasa, A Wietelmann, S Günther, N Doll, T Braun, J Pöling Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice International Journal of Molecular Sciences, 2021-12-29;23(1):. 2021-12-29 [PMID: 35008777] (Western Blot, Mouse)
• S An, I Raju, B Surenkhuu, JE Kwon, S Gulati, M Karaman, A Pradeep, S Sinha, C Mun, S Jain Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies Ocul Surf, 2019-04-06;0(0):. 2019-04-06 [PMID: 30965123] (Neutralization, Mouse)
• Q Liu, Y Du, K Li, W Zhang, X Feng, J Hao, H Li, S Liu Anti-OSM Antibody Inhibits Tubulointerstitial Lesion in a Murine Model of Lupus Nephritis Mediators Inflamm., 2017-05-24;2017(0):3038514. 2017-05-24 [PMID: 28626343] (Neutralization, Mouse)
• Ali Kassem, Catharina Lindholm, Ulf H Lerner Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL PLOS ONE 6/16/2016 [PMID: 27311019]
• Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation Eur J Immunol, 2016-05-12;0(0):. 2016-05-12 [PMID: 27122058] (IHC-Fr, Mouse)
• Mattia Albiero, Nicol Poncina, Stefano Ciciliot, Roberta Cappellari, Lisa Menegazzo, Francesca Ferraro et al. Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M Diabetes 8/1/2015 [PMID: 25804939]
• Guihard P, Boutet M, Brounais-Le Royer B, Gamblin A, Amiaud J, Renaud A, Berreur M, Redini F, Heymann D, Layrolle P, Blanchard F Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am J Pathol, 2015-01-02;185(3):765-75. 2015-01-02 [PMID: 25559270] (IHC, Mouse)
• Le Goff B, Singbrant S, Tonkin B, Martin T, Romas E, Sims N, Walsh N Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine, 2014-04-22;68(2):101-9. 2014-04-22 [PMID: 24767864] (IHC-P, Mouse)
• Tripathi , P, Wang , Y, Coussens , M, Manda , K R, Casey , A M, Lin , C, Poyo , E, Pfeifer , J D, Basappa , N, Bates , C M, Ma , L, Zhang , H, Pan , M, Ding , L, Chen , F Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms. Oncogene, 2013-04-29;33(14):1840-9. 2013-04-29 [PMID: 23624921] (IHC, Mouse)
• Wafa M. Elbjeirami, Luan D. Truong, Ahmad Tawil, Wansheng Wang, Sara Dawson, Hui Y. Lan et al. Early Differential Expression of Oncostatin M in Obstructive Nephropathy Journal of Interferon & Cytokine Research 7/15/2010 [PMID: 20626292]
• Brounais B, David E, Chipoy C, Trichet V, Ferre V, Charrier C, Duplomb L, Berreur M, Redini F, Heymann D, Blanchard F Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 2009-01-03;44(5):830-9. 2009-01-03 [PMID: 19168167] (Neutralization, Mouse, Rat)
• Gard AL, Gavin E, Solodushko V, Pennica D Cardiotrophin-1 in choroid plexus and the cerebrospinal fluid circulatory system. Neuroscience, 2004-01-01;127(1):43-52. 2004-01-01 [PMID: 15219667] (Western Blot, Mouse, Rat)

Bioinformatics

• Gene Symbol: OSM
• Uniprot:
  • P53347()